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Background: Previous clinical studies have revealed the potential of [18F]-fluoro-L-α-methyltyrosine (18F-FAMT) for
the differential diagnosis of malignant tumours from sarcoidosis. However, one concern regarding the differential
diagnosis with 18F-FAMT is the possibility of false negatives given the small absolute uptake of 18F-FAMT that has
been observed in some malignant tumours. The aim of this study was to evaluate a usefulness of dynamic
18F-FAMT positron emission tomography (PET) for differentiating malignant tumours from granulomas.
Methods: Rats bearing both granulomas (Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced) and tumours
(C6 glioma cell-induced) underwent dynamic 2-deoxy-2-[18F]-fluoro-D-glucose (18F-FDG) PET and 18F-FAMT PET for
120 min on consecutive days. Time-activity curves, static images, mean standardized uptake values (SUVs) and the
SUV ratios (SUVRs; calculated by dividing SUV at each time point by that of 2 min after injection) were assessed.
Results: In tumours, 18F-FAMT showed a shoulder peak immediately after the initial distribution followed by gradual
clearance compared with granulomas. Although the mean SUV in the tumours (1.00 ± 0.10) was significantly higher
than that in the granulomas (0.88 ± 0.12), a large overlap was observed. In contrast, the SUVR was markedly higher in
tumours than in granulomas (50 min/2 min, 0.72 ± 0.06 and 0.56 ± 0.05, respectively) with no overlap. The dynamic
patterns, SUVR, and mean SUV of 18F-FDG in the granulomas were comparable to those in the tumours.
Conclusions: Dynamic 18F-FAMT and SUVR analysis might compensate for the current limitations and help in
improving the diagnostic accuracy of 18F-FAMT.
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tomographyBackground
The differential diagnosis of benign from malignant
lesions by using positron emission tomography (PET) is
a problem that remains unsolved because 2-deoxy-2-
[18F]-fluoro-D-glucose (18F-FDG) - the most frequently
applied PET probe for tumour imaging - shows in-
creased uptake in several benign pathologies such as in-
flammatory foci, sarcoidosis, and active tuberculosis
[1,2]. To overcome this limitation, one promising* Correspondence: iida@suzuka-u.ac.jp
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reproduction in any medium, provided the origapproach is the use of 11C/18F-labelled amino acid PET
tracers. In contrast to 18F-FDG, amino acid tracers show
lower uptake in macrophages and other inflammatory
cells [3] and thus have been evaluated for their potential
to differentiate between benign and malignant lesions,
both in animal models and in patients [4-6]. However,
several studies have reported increased uptake of amino
acid tracers in inflammatory lesions including radiation-
induced necrosis [7] and lymphadenopathy in sarcoid-
osis [8]. Therefore, the use of amino acid tracers for the
differential diagnosis has yet to reach a consensus.
In contrast to other amino acid PET tracers, [18F]-
fluoro-L-α-methyltyrosine (18F-FAMT) is selective for L-
type amino acid transporter 1 (LAT-1) and interacts lesss is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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uated sarcoidosis patients with suspected malignancy,
18F-FAMT showed significantly lower uptake in sarcoid-
osis lesions compared to tumour lesions, supporting the
clinical utility of 18F-FAMT for the differential diagnosis
[10]. However, one concern regarding the differential
diagnosis with 18F-FAMT is the possibility of false nega-
tive results, because 18F-FAMT shows relatively small
absolute uptake, even in malignant tumours, which is
occasionally lower than that in sarcoidosis. Therefore, an
alternative parameter that can estimate differences in
18F-FAMT uptake between inflammation and tumours is
needed.
Recently, Zhao et al. [11] reported the usefulness of
dynamic PET imaging of L-11C-methionine (11C-MET;
the most frequently used amino acid tracer) for the dif-
ferential diagnosis of granulomas from malignant
tumours, in rat models. This tracer exhibited a signifi-
cantly different dynamic profile in granulomas compared
to tumours. The success of dynamic PET using 11C-
MET for the differential diagnosis raised the intriguing
possibility that 18F-FAMT could be used as an alternative
amino acid PET tracer. However, the dynamic profile of
18F-FAMT was unknown, and several characteristics of
18F-FAMT, such as the mechanism of transport and
metabolism, could lead to a dynamic profile distinct
from that of 11C-MET. Therefore, in this study, we evalu-
ated the usefulness of dynamic 18F-FAMT PET for the
differentiation of malignant tumours from granulomas in
comparison with 18F-FDG in an experimental rat model.
Methods
Radiopharmaceuticals
The synthesis of 18F-FAMT was performed at the
Gunma University Hospital (Cyclotron Facility) as previ-
ously described [12]. The radiochemical yield and purity
of 18F-FAMT were approximately 20% and 99%, respect-
ively. The 18F-FDG was also produced in the Cyclotron
Facility as previously described [13].
Animal model
All experimental protocols were approved by the Labora-
tory Animal Care and Use Committee of Gunma Univer-
sity. Seven-week-old male Wistar King Aptekman/hok
rats (weight, 240 to 290 g; Japan SLC, Inc., Shizuoka,
Japan) were used in all experiments. We adopted the
Mycobacterium bovis bacillus Calmette-Guérin (BCG)-
induced intramuscular granuloma model that has a simi-
lar histological feature as sarcoidosis [14]. The BCG
strain of Japan (1 × 107 colony-forming unit (CFU); Japan
BCG Laboratory, Tokyo, Japan) was suspended in 0.2 ml
of phosphate-buffered saline [15], or allogenic rat glioma
cells (C6, 2 × 106 cells/0.2 ml) were inoculated into the
left and right calf muscles of the animals to generate a ratmodel bearing both granulomas and tumours. The C6
glioma cell line (RCB2854) was provided by the RIKEN
BRC through the National BioResource Project of the
MEXT, Japan.
Dynamic PET study
At 20 days after the inoculation of BCG and 10 days
after the inoculation of the glioma cells, rats (n = 6) were
kept fasting overnight, anaesthetized with isoflurane, and
injected intravenously with 18F-FDG (11.7 ± 2.57 MBq).
Dynamic PET (list mode acquisition) was performed for
120 min with the hind leg region in the field of view by
using an Inveon PET scanner dedicated to small animal
imaging (Siemens Medical Solutions USA Inc., Knoxville,
TN, USA). The next day, 18F-FAMT (19.4 ± 1.91 MBq)
was injected intravenously, and dynamic PET was per-
formed according to a similar protocol. The injection
doses of 18F-FDG and 18F-FAMT were determined based
on the half-life of 18F (110 min) [11] and the tumour accu-
mulation levels of 18F-FDG and 18F-FAMT.
The data were reconstructed and corrected for attenu-
ation and scatter by using two-dimensional filtered back-
projection. The image matrix was 128 × 128 × 159, which
resulted in a voxel size of 0.77 × 0.77 × 0.796 mm. The
individual time sequence was the following: 4 scans ×
1 min, 3 scans × 2 min, 4 scans × 5 min and 9 scans ×
10 min. For quantitative analysis, images were analysed
by manually drawing volumes of interest (VOIs) in order
to trace the contours of the granulomas and tumours
without correction for partial volume effects. The time-
activity curves, static images (50 to 60 min for 18F-FAMT
and 18F-FDG) and the mean SUVs in the lesions were
calculated. The SUV was determined by using the follow-
ing equation: SUV = activity in a VOI (MBq/cc)/[injected
dose (MBq)/body weight (g)].
To further evaluate the dynamic pattern of 18F-FAMT
uptake, the SUV ratio (SUVR) was determined. The
ratio of SUVs of 18F-FAMT at each time point to that
at 2 min post injection (p.i.) was calculated. The
SUVRs of 18F-FDG were also calculated from the
SUVs at 120 min p.i. relative to that of 2 min p.i.
Immunofluorescent histochemistry
Paraformaldehyde-fixed (4%), paraffin-embedded, 3-μm-
thick tumour and granuloma tissue sections were stained
with haematoxylin and eosin (H&E). Immunofluorescent
staining of the adjacent tissue sections was also
performed according to a standard protocol. Glucose
transporter 1 (GLUT-1) was detected by using an anti-
GLUT-1 polyclonal antibody (rabbit IgG, synthetic pep-
tide, Abcam, Cambridge, UK). LAT-1 was stained by
using an anti-LAT-1 mAb (rabbit IgG, synthetic peptide,
Abcam). The primary antibodies were detected with the
corresponding isotype-specific goat anti-rabbit IgG H&L
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bated with rabbit IgG instead of the primary antibodies
were used as negative controls.
Statistical analyses
Repeated measures analysis of variance was used to as-
sess the significance of differences in the dynamic pat-
terns of 18F-FAMT and 18F-FDG uptake between
granulomas and tumours. A paired t-test was performed
to evaluate the significance of differences in SUVs and




Representative transversal dynamic images of 18F-FAMT
and 18F-FDG are shown in Figure 1. The uptake of
18F-FAMT gradually decreased in both granulomas and
tumours (Figure 1a). In contrast, the uptake of 18F-FDG
gradually increased in both lesions (Figure 1b). The
time-activity curves of the mean SUVs of 18F-FAMT and
18F-FDG in each VOI are shown Figure 2. In the
tumours, 18F-FAMT showed a shoulder peak immedi-
ately after the initial distribution (6 to 15 min and 2 mina
b
TumourGranuloma
1 min 3 min
30 min25 min
TumourGranuloma
1 min 3 min
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Figure 1 Dynamic 18F-FAMT (a) and 18F-FDG (b) images in rats bearing bo
and granuloma (left).p.i., respectively), followed by gradual clearance, whereas
in the granulomas, 18F-FAMT showed slow, exponen-
tial clearance after the initial distribution (2 min; SUV:
1.69 ± 0.25). The dynamic pattern of 18F-FAMT uptake
in the tumours was significantly different from that in
the granulomas or muscles (Figure 2a, p < 0.001). The
dynamic pattern of 18F-FAMT uptake between granu-
lomas and muscles showed no significant differences.
The time-activity curves of 18F-FDG in the granulomas
and tumours exhibited similar patterns and showed no
significant differences (Figure 2b).
Static images of 18F-FAMT-PET and 18F-FDG-PET at
60 min after administration are shown in Figure 3a,b.
Visual and SUV assessments of the static images were
unable to differentiate tumours from granulomas in all
cases, owing to overlaps in 18F-FAMT uptake, although
the mean SUV in the granulomas (0.88 ± 0.12) was sig-
nificantly lower than that in the tumours (1.00 ± 0.10,
p < 0.001, Figure 3c). The static images and the mean
SUVs of 18F-FDG in the granulomas were similar to
those in the tumours (tumour vs. granuloma: 4.25 ±
0.93 vs. 4.00 ± 0.59, p = 0.37, respectively, Figure 3d).
Representative SUVRs are shown in Figure 4. The
SUVRs of 18F-FAMT in tumours were significantly3.0
0.0
6 min 15 min
50 min 70 min
6 min 15 min
50 min 70 min









































Figure 2 Time-activity curves of 18F-FAMT (a) and 18F-FDG (b) in rats bearing tumour and granuloma.
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tumour: 0.72 ± 0.06, granuloma: 0.56 ± 0.05, p < 0.001,
Figure 4a), with no overlap between 20 and 100 min p.i..
The SUVRs in the granulomas and muscles showed no
significant differences and had a considerable overlap
owing to similarities in the dynamic profile. However,
the SUVRs of 18F-FDG in tumours were relatively higher
than those in granulomas (120 min p.i./2 min p.i.,
tumour: 3.57 ± 1.23, granuloma: 2.71 ± 0.60, p = 0.022,
Figure 4b), although there was a substantial overlap.Immunofluorescent histochemistry
High expression levels of LAT-1 were observed in the
tumours (Figure 5a). In contrast, only faint expressions
of LAT-1 were observed in the BCG-induced granu-
lomas (Figure 5d). High expression levels of GLUT-1
were observed on cell membranes in both tumours and
granulomas (Figure 5b,e). Representative images of H&Estaining for the tumours and BCG-induced granulomas
are shown in Figure 5c,f, respectively.
Discussion
We found that dynamic 18F-FAMT PET is useful for dif-
ferentiating granulomas from malignant tumours in a rat
model. The moderate shoulder peak (6 to 15 min p.i.)
and prolonged clearance in the time-activity curves of
18F-FAMT in tumours may reflect the high expression
levels of LAT-1 in malignant lesions as compared to
granulomatous lesions. The high expression levels of
LAT-1 were confirmed by immunohistochemical stain-
ing. These results are consistent with previous clinical
studies that showed a correlation between 18F-FAMT
uptake and the expression levels of LAT-1 [16-18].
Although SUV assessment of 18F-FAMT showed sig-
nificant differences between granulomas and tumours,
the SUV value alone could not reliably provide the dif-































































Figure 3 Static 18F-FAMT (a) and 18F-FDG (b) images in rats bearing granuloma and tumour. Transverse, coronal and sagittal images of 18F-FAMT
and 18F-FDG (50 to 60 min). White arrow: locations of C6 tumour (right) and granuloma (left). Individual values of SUV for 18F-FAMT (c) and 18F-FDG
(d) in granuloma and tumour lesion (50 to 60 min p.i.). Significant differences were determined (**p < 0.005; N.S., not statistically significant).
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stantially. It should be noted that unlike a clinical study
of sarcoidosis patients [10], in our granuloma model,
18F-FAMT accumulated in the granulomas at 60 min p.i.























Figure 4 Individual values of SUVR for 18F-FAMT (50 min/2 min) (a) and 18F-F
(*p < 0.05; **p < 0.005; N.S., not statistically significant).increased local blood flow and LAT-1, one possible
explanation for this difference is the effect of the con-
centration of radioactivity in the blood. However, even
in the clinical study, the SUVs of 18F-FAMT in lung can-







































Figure 5 Microscopy images (×40) of immunofluorescent staining of LAT-1 (tumour (a), granuloma (d)), GLUT-1 (tumour (b), granuloma (e)) and
H&E staining (tumour (c), granuloma (f)). White arrowhead: cancer cell; black arrow: lymphocyte infiltration; white arrow: epithelioid cell granuloma.
Bars indicate 50 μm.
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imal SUVs, even in malignant lesions, the sensitivity of
18F-FAMT is lower than that of 18F-FDG [18,19]. Thus,
a more definitive indicator that can improve the accur-
acy of the differential diagnosis is needed.
To address this issue, we evaluated the SUVR of
18F-FAMT relative to the SUV of 2 min p.i. and found
that the overlap in SUVRs diminished and showed a
significant difference in most of acquisition times
(3 min p.i. to 120 min p.i.) because of prolonged
retention of 18F-FAMT in the tumours. The SUVR ap-
peared to depend on the existence of specific uptake,
because there were no significant differences in the
SUVRs between granulomas and muscle tissue where
specific uptake was absent. These data suggested that
the dynamic profile of 18F-FAMT in malignant lesions
could reflect LAT-1-dependent specific uptake, regard-
less of the maximal SUV. Therefore, we believe that
SUVR will be useful for differential diagnosis even if
the maximal SUV is low. However, the calculation
points should be optimized for each lesion, because
differences between species or types of cancer might
affect the absolute uptake or clearance rate of 18F-
FAMT. Therefore, it is worth performing a clinical
study to investigate whether SUVR measurement can
improve the sensitivity of 18F-FAMT.
As predicted, 18F-FDG showed comparable time-
activity curve patterns, SUVs and expression levels of
GLUT-1 in tumours and granulomas. Although the
SUVRs of 18F-FDG in the tumours were slightly higher
than those in the granulomas, there was a considerable
overlap. Therefore, 18F-FDG may provide less reliable in-
formation for the differential diagnosis, even if dynamicimaging is performed. These data support that BCG-
induced granulomas could serve as a proper model for
the differential diagnosis of tumours from inflammation,
as was used in a study of 11C-MET [12].
However, unlike 11C-MET, which tended to be
retained in both lesions after the initial distribution,
18F-FAMT showed slow, exponential clearance from
both lesions. This difference might be attributed to the
transport mechanism and metabolic pathway of the
tracers. Indeed, 11C-MET can be a substrate for vari-
ous transporters such as system L, A, ASC and y + L
[20,21]. Additionally, following incorporation, 11C-MET
is rapidly metabolized and trapped inside the cells
[22]. These properties of 11C-MET may result in the
retention of the tracer, both in tumours and in normal
tissues. In contrast, 18F-FAMT is incorporated into
cancer cells solely via LAT-1, which functions as a bi-
directional transporter with an obligatory exchange
mechanism [5,23]. The transport activity depends on
the availability of intracellular exchange substrates with
similar influx and efflux selectivity. Once incorporated,
18F-FAMT remained intact in cells for up to 60 min,
and it was metabolized to protein to only a small ex-
tent [24]. These characteristics might cause a gentle
decrease in 18F-FAMT in tumour cells along with a
decrease in the concentration of 18F-FAMT in plasma.
However, regardless of these properties, 18F-FAMT also
showed distinct dynamic profiles in tumours and
granulomas as 11C-MET did. Thus our results impli-
cate potential wide applicability of dynamic PET for
the differential diagnosis, even for the other amino
acid tracers that show slow exponential clearance from
the tumours.
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reliable imaging method for distinguishing tumours from
granulomas, compared to conventional static images.
Thus, dynamic 18F-FAMT PET in addition to standard
18F-FDG-PET would increase the accuracy of the differ-
ential diagnosis of malignant tumours from sarcoidosis,
radiation-induced necrosis and tuberculosis. As dynamic
18F-FAMT showed comparable results to 11C-MET, clin-
ical studies evaluating the applicability of dynamic amino
acid PET for the differential diagnosis will be the object-
ive of future research.
Conclusions
The dynamic profile of 18F-FAMT showed significant
differences between tumours and granulomas. Add-
itionally, SUVR of 18F-FAMT diminished the overlap
between tumours and granulomas, which has been
observed in SUV analysis. These results indicate that
dynamic 18F-FAMT and SUVR analysis might compen-
sate for current imaging limitations and help with
improving the diagnostic accuracy of 18F-FAMT.
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